Organigram (CVE:OGI) had its target price hoisted by Eight Capital from C$4.50 to C$7.00 in a research report issued on Monday. Eight Capital’s price objective suggests a potential upside of 61.66% from the stock’s current price.
Separately, Canaccord Genuity set a C$5.50 target price on Organigram in a research report on Wednesday, March 7th.
Shares of Organigram (OGI) traded up C$0.02 during mid-day trading on Monday, reaching C$4.33. The company had a trading volume of 342,290 shares, compared to its average volume of 2,237,305. The firm has a market capitalization of $526.95, a price-to-earnings ratio of -39.27 and a beta of 8.35. Organigram has a 1 year low of C$2.00 and a 1 year high of C$5.68.
OrganiGram Holdings Inc, through its subsidiary, Organigram Inc, produces and sells medical marijuana in Canada. The company was founded in 2013 and is based in Moncton, Canada.
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.